Medicus Pharma (NASDAQ:MDCX) Raised to Strong-Buy at D Boral Capital

Medicus Pharma (NASDAQ:MDCX) was upgraded by equities researchers at D Boral Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other research firms have also recently issued reports on MDCX. D. Boral Capital initiated coverage on Medicus Pharma in a research note on Monday. They set a “buy” rating and a $14.00 target price on the stock. Brookline Capital Management raised shares of Medicus Pharma to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Maxim Group initiated coverage on shares of Medicus Pharma in a research report on Tuesday, December 17th. They issued a “buy” rating and a $10.00 target price for the company.

Medicus Pharma Stock Performance

Shares of Medicus Pharma stock opened at $3.65 on Monday. The stock has a fifty day moving average price of $3.48. Medicus Pharma has a 12-month low of $1.80 and a 12-month high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.14. Research analysts expect that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC bought a new stake in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma makes up 1.3% of Interchange Capital Partners LLC’s holdings, making the stock its 15th largest position. Interchange Capital Partners LLC owned 13.43% of Medicus Pharma as of its most recent SEC filing.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.